After TGN1412: Recent developments in cytokine release assays

References

• Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C. H., Hanke, T., Hünig, T., Kerkau, T., Gold, R. 2005. Selective targeting of regulatory T-cells with CD28 super-agonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. 202:445–455.
   PubMed Web of Science ®Google Scholar
• Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., Daëron, M. 2009. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716–3725.
   PubMed Web of Science ®Google Scholar
• Campbell, J. J., Murphy, K. E., Kunkel, E. J., Brightling, C. E., Soler, D., Shen, Z., Boisvert, J., Greenberg, H. B, Vierra, M. A, Goodman, S. B, Genovese, M. C, Wardlaw, A. J, Butcher, E. C, Wu, L 2001. CCR7 expression and memory T cell diversity in humans. J. Immunol. 166:877–884.
   PubMed Web of Science ®Google Scholar
• Cerf-Bensussan, N., Guy-Grand, D. 1991. Intestinal intra-epithelial lymphocytes. Gastroenterol. Clin. North Am. 20:549–576.
   PubMed Web of Science ®Google Scholar
• Chatenoud, L., Ferran, C., Legendre, C., Thouard, I., Merite, S., Reuter, A., Gevaert, Y., Kreis, H., Franchimont, P., Bach, J. F. 1990. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49:697–702.
   PubMed Web of Science ®Google Scholar
• CHMP (Committee for Medicinal Products for Human Use). 2007. Guideline on Strategies to Identify and Mitigate Risks for First-In-Human Clinical Trials with Investigational Medicinal Products. Available online at: http://www.ema.europa.eu/pdfs/human/swp/2836707enfin.pdf.
   Google Scholar
• Chung, C. H. 2008. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13:725–732.
   PubMed Web of Science ®Google Scholar
• Dhir, V., Fort, M., Mahmood, A., Higbee, R., Warren, W., Narayanan, P., Wittman, V. 2012. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. J. Immunotoxicol. 9:34–42.
   PubMed Web of Science ®Google Scholar
• Duff, G. W. 2006. Expert Group on Phase One Clinical Trials: Final report. Norwich, UK: TSO Publications Centre.
   Google Scholar
• Dustin, M. L., Olszowy, M. W., Holdorf, A. D., Li, J., Bromley, S., Desai, N., Widder, P., Rosenberger, F., van der Merwe, P. A., Allen, P. M., Shaw, A. S. 1998. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell 94:667–677.
   PubMed Web of Science ®Google Scholar
• Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., Stebbings, R. 2010. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br. J. Pharmacol. 161:512–526.
   PubMed Web of Science ®Google Scholar
• Findlay, L., Eastwood, D., Ball, C., Robinson, C. J., Bird, C., Wadhwa, M., Thorpe, S. J., Thorpe, R., Stebbings, R., Poole, S. 2011a. Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. J. Immunol. Meth. 371:134–142.
   PubMed Web of Science ®Google Scholar
• Findlay, L., Eastwood, D., Stebbings, R., Sharp, G., Mistry, Y., Ball, C., Hood, J., Thorpe, R., Poole, S. 2010. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J. Immunol. Meth. 352:1–12.
   PubMed Web of Science ®Google Scholar
• Findlay, L., Sharp, G., Fox, B., Ball, C., Robinson, C. J., Bird, C., Stebbings, R., Eastwood, D., Wadhwa, M., Poole, S., Thorpe, R., Thorpe, S. J. 2011b. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. Cytokine 55:141–151.
   Google Scholar
• Geginat, J., Sallusto, F., Lanzavecchia, A. 2001. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4+ T-cells. J. Exp. Med. 194:1711–1719.
   PubMed Web of Science ®Google Scholar
• Hanke, T. 2006. Lessons from TGN1412. Lancet 368:1569–1570.
   PubMed Web of Science ®Google Scholar
• Jenkins, M. K., Taylor, P. S., Norton, S. D., Urdahl, K. B. 1991. CD28 delivers a co-stimulatory signal involved in antigen-specific IL-2 production by human T-cells. J. Immunol. 147:2461–2466.
   PubMed Web of Science ®Google Scholar
• Lin, C. H., Hünig, T. 2003. Efficient expansion of regulatory T-cells in vitro and in vivo with a CD28 super-agonist. Eur. J. Immunol. 33:626–638.
   PubMed Web of Science ®Google Scholar
• Lühder, F., Huang, Y., Dennehy, K. M., Guntermann, C., Müller, I., Winkler, E., Kerkau, T., Ikemizu, S., Davis, S. J., Hanke, T., Hünig, T. 2003. Topological requirements and signaling properties of T-cell-activating, anti-CD28 antibody super-agonists. J. Exp. Med. 197:955–966.
   PubMed Web of Science ®Google Scholar
• Moniuszko, M., Fry, T., Tsai, W. P., Morre, M., Assouline, B., Cortez, P., Lewis, M. G., Cairns, S., Mackall, C., Franchini, G. 2004. Recombinant IL-7 induces proliferation of naive macaque CD4+ and CD8+ T-cells in vivo. J. Virol. 78:9740–9749.
   PubMed Web of Science ®Google Scholar
• Monks, C. R., Freiberg, B. A., Kupfer, H., Sciaky, N., Kupfer, A. 1998. Three-dimensional segregation of supramolecular activation clusters in T-cells. Nature 395:82–86.
   PubMed Web of Science ®Google Scholar
• Moreau, T., Coles, A., Wing, M., Isaacs, J., Hale, G., Waldmann, H., Compston, A. 1996. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119:225–237.
   PubMed Web of Science ®Google Scholar
• Picker, L. J. 2006. Immunopathogenesis of acute AIDS virus infection. Curr. Opin. Immunol. 18:399–405.
   PubMedGoogle Scholar
• Pitcher, C. J., Hagen, S. I., Walker, J. M., Lum, R., Mitchell, B. L., Maino, V. C., Axthelm, M. K., Picker, L. J. 2002. Development and homeostasis of T-cell memory in rhesus macaque. J. Immunol. 168:29–43.
   PubMedGoogle Scholar
• Rodríguez-Palmero, M., Hara, T., Thumbs, A., Hünig, T. 1999. Triggering of T-cell proliferation through CD28 induces GATA-3 and promotes T-helper type 2 differentiation in vitro and in vivo. Eur. J. Immunol. 29:3914–3924.
   PubMed Web of Science ®Google Scholar
• Römer, P. S., Berr, S., Avota, E., Na, S. Y., Battaglia, M., ten Berge, I., Einsele, H., Hünig, T. 2011. Pre-culture of PBMC at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 super-agonist TGN1412. Blood 118:6772–6782.
   PubMed Web of Science ®Google Scholar
• Sallusto, F., Geginat, J., Lanzavecchia A. 2004. Central memory and effector memory T-cell subsets: Function, generation, and maintenance. Annu. Rev. Immunol. 22:745–763.
   PubMed Web of Science ®Google Scholar
• Sallusto, F., Lenig, D., Förster, R., Lipp, M., Lanzavecchia, A. 1999. Two subsets of memory T-lymphocytes with distinct homing potentials and effector functions. Nature 401:708–712.
   PubMed Web of Science ®Google Scholar
• Sanchez-Lockhart, M., Miller, J. 2006. Engagement of CD28 outside of the immunological synapse results in up-regulation of IL-2 mRNA stability but not IL-2 transcription. J. Immunol. 176:4778–4784.
   PubMed Web of Science ®Google Scholar
• Sandilands, G. P., Wilson, M., Huser, C., Jolly, L., Sands, W. A., McSharry, C. 2010. Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy? Clin. Exp. Immunol. 162:516–527.
   PubMed Web of Science ®Google Scholar
• Smit-McBride, Z., Mattapallil, J. J., McChesney, M., Ferrick, D., Dandekar, S. 1998. Gastrointestinal T-lymphocytes retain high potential for cytokine responses but have severe CD4+ T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J. Virol. 72:6646–6656.
   PubMedGoogle Scholar
• Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., Fox, B., Tarrant, G., Robinson, J., Meager, T., Dolman, C., Thorpe, S. J., Bristow, A., Wadhwa, M., Thorpe, R., Poole, S. 2007. “Cytokine storm” in the Phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve pre-clinical testing of immunotherapeutics. J. Immunol. 179:3325–3331.
   PubMed Web of Science ®Google Scholar
• Stebbings, R., Poole, S., Thorpe, R. 2009. Safety of biologics, lessons learnt from TGN1412. Curr. Opin. Biotechnol. 20:673–677.
   PubMedGoogle Scholar
• Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., Panoskaltsis, N. 2006. “Cytokine storm” in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New Engl. J. Med. 355:1018–1028.
   PubMed Web of Science ®Google Scholar
• Suthanthiran, M., Fotino, M., Riggio, R. R., Cheigh, J. S., Stenzel, K. H. 1989. OKT3-associated adverse reactions: Mechanistic basis and therapeutic options. Am. J. Kidney Dis. 14:39–44.
   PubMedGoogle Scholar
• Tacke, M., Hanke, G., Hanke, T., Hünig, T. 1997. CD28-mediated induction of proliferation in resting T-cells in vitro and in vivo without engagement of the T-cell receptor: Evidence for functionally distinct forms of CD28. Eur. J. Immunol. 27:239–247.
   PubMed Web of Science ®Google Scholar
• TeGenero, A. G. 2005. TGN1412 investigator’s brochure. Available online at: http://www.circare.org/foia5/tgn1412investigatorbrochure.pdf. Accessed 5 March 2012.
   Google Scholar
• Thoulouze, M. I., Sol-Foulon, N., Blanchet, F., Dautry-Varsat, A., Schwartz, O., Alcover, A. 2006. Human immunodeficiency virus type-1 infection impairs the formation of the immune-logical synapse. Immunity 24:547–561.
   PubMedGoogle Scholar
• Waibler, Z., Sender, L. Y., Kamp, C., Müller-Berghaus, J., Liedert, B., Schneider, C. K., Löwer, J., Kalinke, U. 2008. Toward experimental assessment of receptor occupancy: TGN1412 revisited. J. Allergy Clin. Immunol. 122:890–892.
   PubMed Web of Science ®Google Scholar
• Walker, M. R., Makropoulos, D. A., Achuthanandam, R., Van Arsdell, S., Bugelski, P. J. 2011. Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 super-agonists using multiplex cytokine and hierarchical cluster analysis. Int. Immunopharmacol. 11:1697–1705.
   PubMedGoogle Scholar
• Wang, D., Matsumoto, R., You, Y., Che, T., Lin, X. Y., Gaffen, S. L., Lin, X. 2004. CD3/CD28 costimulation-induced NF-κB activation is mediated by recruitment of protein kinase C-θ, Bcl10, and IκB kinase β to the immunological synapse through CARMA1. Mol. Cell. Biol. 24:164–171.
   PubMed Web of Science ®Google Scholar
• Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., Compston, A. 1996. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest. 98:2819–2826.
   PubMed Web of Science ®Google Scholar
• Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., Engert, A. 1999. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94:2217–2224.
   PubMed Web of Science ®Google Scholar